Yara Maria Machlah

Yara Maria Machlah

Auto-generated profile, based on publicly available information

Yara Maria Machlah

Department of Endocrinology, Diabetology and Metabolism, Endocrine Tumor Center at the West German Cancer Center, University Hospital Essen, University of Duisburg-Essen , 45147 Essen

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 May 2026 in Endocrine
Verified
Journal Article
Open access
SSSusanne Singer
Susanne Singer
KTKatherine Taylor
Katherine Taylor
YMYara Maria Machlah
Yara Maria Machlah
TBTim Brandenburg
Tim Brandenburg
KLKerstin Lorenz
Kerstin Lorenz
FEFriederike Eilsberger
Friederike Eilsberger
Background: Because anaplastic thyroid cancer (ATC) is a rare diagnosis, detailed epidemiological data are difficult to find in publicly accessible platforms. The aim of this study was to report current incidence and survival estimates for ATC in Germany and to analyse their trends over time. Methods: Data from the population-based cancer registries in Germany were pooled. ATC was classified according to the International Classification of Diseases, 10th edition (ICD-10). Age-standardised incidence rates (per 100,000) for the years 2011 to 2022 were calculated. The relative survival was estimated using period analysis. Annual percentage changes (APC) in the incidence and survival trends over time were computed. Findings: The number of new ATC cases diagnosed between 2011 and 2022 was 2127 (924 in men and 1203 in women). The current raw incidence is 0.19 in men and 0.22 in women. The age-standardised incidence in men changed slightly, but not significantly, during this period (APC − 2%, p = 0.126; recent rate 0.11) while it decreased in women (APC − 3%, p < 0.001; recent rate 0.10). The five-year relative survival ranged from 11% (2020–2022) to 15% (2017–2019) and decreased considerably with age. There were no differences in survival between men and women and no evidence for a change in survival over time. Conclusion: About two persons per 1 million inhabitants are currently diagnosed with ATC per year. Over the past 12 years, there was a slight decrease in ATC incidence, especially in women, while survival remained largely unchanged during this period.

26 November 2025 in European Journal of Endocrinology
Verified
Journal Article
Closed access
YMYara Maria Machlah
Yara Maria Machlah
LSLynn Marlene Srasra
Lynn Marlene Srasra
STSarah Theurer
Sarah Theurer
FWFrank Weber
Frank Weber
HLHarald Lahner
Harald Lahner
TBTim Brandenburg
Tim Brandenburg
Objective: Selective RET inhibition with selpercatinib significantly improved outcomes in advanced RET-mutant medullary thyroid cancer (MTC). However, data from endocrine oncology practice are limited, particularly in heterogeneous treatment-naive and pretreated patients. Evaluating real-world effectiveness and safety is essential to reaffirm clinical trial results. Design: Retrospective, single-center study. Methods: We analyzed patients with RET-mutant MTC treated with selpercatinib between March 2021 and May 2025 at the Essen Endocrine Tumor Center. Clinical characteristics, treatment outcomes as well as frequency and longitudinal course of adverse events (AEs) were assessed. Results: Thirty-one patients with advanced RET-mutant MTC (87% with distant metastases; median age 54 years; 84% sporadic) were included. First-line selpercatinib (52%) treatment resulted in significantly longer median progression-free survival (PFS) (not reached vs. 18.3 months) and higher objective response rate (ORR) (81% vs. 33%) compared to later-line use. One-year PFS rate was 100% for first-line and 60% for further-line treatment. ORR was significantly higher in patients without bone metastases (90% vs 43%). Age at treatment initiation, sex, and RET mutation subtype did not impact ORR or PFS. The most common AEs included hypertension (58.6%) and erectile dysfunction (55.6%). Grade ≥3 events occurred in 37.5% of patients, with hypertension most frequent. Treatment interruptions and dose reductions were required in 22.6% of patients, primarily due to QTc prolongation and fatigue. Three patients (9.7%) discontinued treatment permanently due to AEs. Conclusions: In real-word settings, selpercatinib showed high efficacy and tolerability, particularly as first-line treatment. Our findings support its use as the preferred initial targeted treatment for RET-driven MTC beyond clinical trial populations.

23 May 2025 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
YMYara Maria Machlah
Yara Maria Machlah
TBTim Brandenburg
Tim Brandenburg
PMPhilipp Muchalla
Philipp Muchalla
VTVera Tiedje
Vera Tiedje
STSarah Theurer
Sarah Theurer
DFDagmar Führer-Sakel
Dagmar Führer-Sakel
Purpose: Multikinase inhibitors (MKIs) have transformed treatment for advanced radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) and medullary thyroid cancer (MTC). However, limited insight exists into management differences between expert centers and multicenter registries or clinical studies. Moreover, MKI efficacy in poorly differentiated thyroid cancer (PDTC) is underreported. Methods: This retrospective analysis included 154 patients with thyroid cancer (51 PDTC, 49 DTC, 54 MTC) treated with MKIs from 2011 to 2024 at the Essen Endocrine Tumor Center by a consistent specialist team. Clinical characteristics, tumor genetics, time to treatment, and treatment outcomes were assessed. Cox regression analyses identified prognostic survival factors. Results: In (P)DTC, lenvatinib showed higher objective response rate (ORR) (64% vs 18%) and longer median progression-free survival (PFS) (22.4 vs 6.7 months) than sorafenib, especially in PDTC (21.2 vs 3.5 months). Lenvatinib-treated patients without bone metastases had higher ORR (74% vs 53%), while higher age and liver metastases were associated with shorter PFS (HR, 2.12, P = .039; HR, 2.34, P = .031). In MTC, vandetanib demonstrated higher ORR (60% vs 18%) and longer PFS (26.1 vs 10.0 months) than cabozantinib. Vandetanib as first-line showed higher ORR (67% vs 25%) and RET mutations correlated with longer PFS (HR, 0.14, P = .045). Conclusion: Lenvatinib outperformed sorafenib, particularly in PDTC, suggesting the need for alternative treatments. In MTC, vandetanib was more effective than cabozantinib, supporting its use as first-line therapy. However, the choice of MKI was determined by the treating physician. Our data highlight MKI effectiveness under expert-center management compared to prior trials and real-world data.

21 April 2026 in The Journal of Clinical Endocrinology & Metabolism
Verified
Journal Article
Closed access
KGKatharina Elisabeth Graf
Katharina Elisabeth Graf
PAPia Adam
Pia Adam
FMFelix Megerle
Felix Megerle
YMYara Maria Machlah
Yara Maria Machlah
DSDominik Soll
Dominik Soll
MKMatthias Kroiss
Matthias Kroiss
Context: Prognosis of anaplastic thyroid cancer (ATC) remains poor. In the absence of immediately actionable molecular alterations, guidelines recommend multimodal therapy including radiotherapy and cytotoxic chemotherapy, but optimal regimens are not established. Many centers in Germany have adopted carboplatin/paclitaxel (CP), with or without radiotherapy, as a preferred first-line approach. Objective: This study aims to compare the outcome of patients treated first-line with CP ± radiotherapy vs other cytotoxic chemotherapy regimens in ATC. Design: Retrospective multicenter registry study in Germany. Setting and patients: 158 adults with histologically confirmed ATC treated with first-line cytotoxic chemotherapy at 7 German tertiary centers (2000-2024). Main Outcome Measures: Progression-free survival (PFS) and overall survival (OS) were compared with Kaplan–Meier and log-rank tests; a Cox proportional hazard model was used to identify risk factors. Results: 97 patients received first-line CP, and 61 received other chemotherapy. PFS (102 vs 89 days; log-rank P = .23) and OS (278 vs 295 days; P = .50) did not differ between CP and other regimens. Complete response occurred in 13% with CP and 8% with other chemotherapy (P = .46). In multivariable analyses, age ≥65 years, lymph node metastasis, and distant metastasis were associated with higher mortality risk. Surgery was associated with a lower mortality risk. CP was not associated with improved OS. The outcome of second-line treatment was not different for chemotherapy vs kinase inhibition ± immunotherapy. Conclusion: In this registry study, CP showed no survival benefit in ATC; outcomes depended on disease burden and resectability, underscoring the need for rapid molecular diagnostics. Chemotherapy may serve as a bridging strategy.

16 January 2026 in Endocrine-Related Cancer
Verified
Journal Article
Closed access
YMYara Maria Machlah
Yara Maria Machlah
LSLynn Marlene Srasra
Lynn Marlene Srasra
STSarah Theurer
Sarah Theurer
FWFrank Weber
Frank Weber
DKDavid Kersting
David Kersting
TBTim Brandenburg
Tim Brandenburg
Cabozantinib has significantly improved progression-free survival (PFS) in patients with radioiodine-refractory differentiated thyroid cancer (RAIR-DTC) after lenvatinib and/or sorafenib pretreatment in the phase 3 COSMIC-311 trial, leading to its approval for sequential treatment. Real-world evidence of cabozantinib remains limited, particularly in poorly differentiated thyroid cancer (PDTC). In this retrospective analysis, we included adult patients with RAIR-DTC or PDTC treated with cabozantinib as further-line treatment at the Essen Endocrine Tumor Center (June 2022–July 2025). All patients had received prior targeted therapy and had documented progressive disease at cabozantinib initiation. Best overall response, PFS, overall survival (OS) and adverse events were assessed. Nineteen patients (7 DTC and 12 PDTC) were included in the safety analysis, and 17 patients were included in the efficacy assessment. Under sequential cabozantinib treatment, partial response (PR) was observed in 4/17 (24%): 3/4 in patients switched due to lenvatinib toxicity and 1/13 in those switched due to progression. Median PFS was 5.4 months in DTC and 3.6 months in PDTC. Median OS from cabozantinib initiation was 13.5 months in DTC and 15.8 months in PDTC. Dose reductions or interruptions were required in 6/19 (31.6%), and 3/19 (15.8%) permanently discontinued cabozantinib due to toxicity. In this real-world cohort, further-line cabozantinib showed limited efficacy in RAIR-(P)DTC, especially in PDTC. Responses were more favorable when cabozantinib was initiated due to prior treatment toxicity rather than progression. The substantial toxicity highlights the need for careful management and improved therapeutic strategies in this population.